Trials / Completed
CompletedNCT02421172
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to placebo. The study has two periods to explore preliminary dose effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CJM112 | CJM112 Fully human IgG1 monoclonal antibody |
| DRUG | Placebo |
Timeline
- Start date
- 2015-04-13
- Primary completion
- 2016-11-23
- Completion
- 2016-11-23
- First posted
- 2015-04-20
- Last updated
- 2022-07-13
- Results posted
- 2019-05-23
Locations
16 sites across 5 countries: United States, Denmark, Germany, Netherlands, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02421172. Inclusion in this directory is not an endorsement.